HORIBA, Ltd. (Headquarters in Kyoto, Japan, referred to as HORIBA) and HORIBA Instruments (Headquarters in Irvine, California, USA) announced today that it has acquired MedTest Holdings, Inc. (Headquarters in Canton, MI, USA, composed of MedTest Dx, Inc., Pointe Scientific, Inc., Clinitox Diagnostix, Inc., and Medical Laboratory Solutions, Inc.).
The acquisition will combine the complementary innovative technology offerings of the HORIBA Medical segment (referred to as HORIBA Medical) with MedTest Dx technology, Clinitox, and Pointe Scientific’s R&D and manufacturing capabilities, with particular expertise in FDA 510K and CLIA clearances, to address the multidisciplinary requirements of IVD※1 testing customers.
“Our long term vision and continuous investments coupled with our outstanding employees have resulted in pursuing innovative Chemistry and Immunochemistry technology solutions. I am extremely pleased that this long term vision has resulted in acquiring MedTest,” said Mr. Atsushi Horiba, Chairman & Group CEO of HORIBA, Ltd.
“This acquisition provides HORIBA Medical the opportunity to address the IVD market’s multidisciplinary requirements along with the complementary innovative technology of Pointe Scientific and MedTest’s high quality Chemistry solutions. HORIBA Medical will continue offering innovative technology solutions through its Yumizen※2 brand and current distribution channels,” said HORIBA Medical segment leader Dr. Jai Hakhu, Chairman and CEO of HORIBA Instruments Incorporated and President of HORIBA ABX SAS in France.
HORIBA Medical will continue investing in innovative technologies for future IVD requirements.
This article was written by Medilink Midlands Patron, HORIBA.
For more information on Medilink Midlands Patronage, click here
